Latest news
Debiopharm and Aspen Partner to Launch Prostate Cancer Drug Trelstar® in South Africa
Debiopharm & Dexa Medica Launch Triptorelin Collaboration to Bring New Hope To Women With Endometriosis
Debiopharm partners with Verity Pharmaceuticals for the exclusive US commercialization of Trelstar® for Prostate Cancer
Knight Partners with Debiopharm for the Commercialization of Trelstar® in Canada
Debiopharm and Ipsen extend their strategic Decapeptyl® (triptorelin) partnership for another 15 years
Debiopharm Group regains the commercial rights to Trelstar® (Triptorelin pamoate) and looks for new partners in North America
Arbor Pharmaceuticals, LLC and Debiopharm International SA Announce Commercial Availability of Triptodur™, Triptorelin 6-month Formulation, for Treatment of Central Precocious…
Debiopharm International SA and Arbor Pharmaceuticals, LLC Announce U.S. FDA Approval for Triptodur™, Triptorelin 6-month Formulation, in the Treatment of…
Debiopharm Group’s Triptorelin 6-month Formulation Receives Approval for the Treatment of Central Precocious Puberty (CPP) in Europe